التفاصيل البيبلوغرافية
| العنوان: |
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma |
| المؤلفون: |
Ilaria Saltarella, Vanessa Desantis, Assunta Melaccio, Antonio Giovanni Solimando, Aurelia Lamanuzzi, Roberto Ria, Clelia Tiziana Storlazzi, Maria Addolorata Mariggiò, Angelo Vacca, Maria Antonia Frassanito |
| المصدر: |
Cells; Volume 9; Issue 1; Pages: 167 |
| بيانات النشر: |
Multidisciplinary Digital Publishing Institute |
| سنة النشر: |
2020 |
| المجموعة: |
MDPI Open Access Publishing |
| مصطلحات موضوعية: |
multiple myeloma, CD38 antigen, daratumumab, drug resistance |
| الوصف: |
Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients undergo progression. Dara exerts anti-MM activity via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and immunomodulatory effects. Deregulation of these pleiotropic mechanisms may cause development of Dara resistance. Knowledge of this resistance may improve the therapeutic management of MM patients. |
| نوع الوثيقة: |
text |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| العلاقة: |
Cellular Pathology; https://dx.doi.org/10.3390/cells9010167Test |
| DOI: |
10.3390/cells9010167 |
| الإتاحة: |
https://doi.org/10.3390/cells9010167Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.C692DD36 |
| قاعدة البيانات: |
BASE |
